upadacitinib + prednisolone

Upadacitinib + prednisolone is a combination of two pharmaceutical drugs used together, primarily in the management of moderate-to-severe atopic dermatitis and potentially other inflammatory or autoimmune diseases. **Upadacitinib** is a selective Janus kinase 1 (JAK1) inhibitor, which blocks the JAK-STAT signaling pathway involved in immune activation and inflammation, thereby reducing the production of pro-inflammatory cytokines[2][4][5]. **Prednisolone** is a synthetic glucocorticoid corticosteroid that exerts anti-inflammatory and immunosuppressive effects through activation of the glucocorticoid receptor, broadly suppressing cytokine transcription and many aspects of the immune response. The combination aims to leverage the targeted actions of upadacitinib with the broader immunosuppressive efficacy of prednisolone. No unique approved brand name, code name, or proprietary combination product identified; its use is as an off-label or clinical trial strategy.